A Synbiotic Combining Chitin-Glucan and Lactobacillus acidophilus NCFM Induces a Colonic Molecular Signature Soothing Intestinal Pain and Inflammation in an Animal Model of IBS.
[en] Chitin-glucan (CG) is a new generation of prebiotic. Lactobacillus acidophilus NCFM(®) (NCFM) is a probiotic with the ability to decrease abdominal pain. We evaluate the functional and molecular gastrointestinal responses to a synbiotic administration combining CG and NCFM in a rat model of long-lasting colon hypersensitivity. The intracolonic pressure was assessed during the 9-week experiment in animals receiving CG in association or not with NCFM and compared to that in Lacticaseibacillus paracasei Lpc-37(®)-treated animals and control rats receiving tap water. The effects of the synbiotic were evaluated using the Wallace score, the quantification of colon myeloperoxidase (MPO) and the master genes driving analgesia and inflammation. CG 1.5 alone and NCFM 10(9) colony forming units (CFU) alone similarly decreased the visceral pain sensitivity. Lpc-37 had no significant effect. The best profile of pain perception inhibition was obtained with the combination of CG 1.5 g and NCFM 10(9) CFU, confirming a synbiotic property. This synbiotic treatment significantly reduced macroscopic colonic lesions and MPO concentrations, and induced master genes involved in analgesia (CB1, CB2, MOR, PPARα), with a downregulation of inflammatory cytokines (IL-1β, TNFα) and an induction of IL-10 and PPARγ. In conclusion, CG 1.5 g + NCFM 10(9) CFU significantly decreased visceral pain perception and intestinal inflammation through the regulation of master genes.
Disciplines :
Gastroenterology & hepatology
Author, co-author :
Capirchio, Lena; Hepato-Gastroenterology Department, Centre Hospitalier Wallonie-Picarde, 7500 Tournai, Belgium.
Rousseaux, Christel ; Intestinal Biotech Development, 59045 Lille, France.
Dubuquoy, Caroline; Intestinal Biotech Development, 59045 Lille, France.
Ouwehand, Arthur C ; Health Sciences, IFF Health, 02460 Kantvik, Finland.
Maquet, Véronique; KitoZyme SA, Parc Industriel des Hauts Sarts Zone 2, Rue de Milmort 680, 4040 Herstal, Belgium.
Modica, Salvatore; KitoZyme SA, Parc Industriel des Hauts Sarts Zone 2, Rue de Milmort 680, 4040 Herstal, Belgium.
Louis, Edouard ; Université de Liège - ULiège > Département des sciences cliniques > Hépato-gastroentérologie
Desreumaux, Pierre; U1286-INFINITE-Institute for Translational Research in Inflammation, University Lille, Inserm, CHU Lille, 59000 Lille, France. ; Hepato-Gastroenterology Department, Lille University Hospital, 59000 Lille, France.
Tack, Jan; Translational Research Center for Gastrointestinal Disorders (TARGID), KU Leuven, 3000 Leuven, Belgium. ; Department of Molecular and Clinical Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, 40530 Gothenburg, Sweden. ; Rome Foundation, Raleigh, NC 27614, USA.
Language :
English
Title :
A Synbiotic Combining Chitin-Glucan and Lactobacillus acidophilus NCFM Induces a Colonic Molecular Signature Soothing Intestinal Pain and Inflammation in an Animal Model of IBS.
Publication date :
05 October 2024
Journal title :
International Journal of Molecular Sciences
ISSN :
1661-6596
eISSN :
1422-0067
Publisher :
Multidisciplinary Digital Publishing Institute (MDPI), Ch
Fortea J. Prior M. Irritable bowel syndrome with constipation: A European-focused systematic literature review of disease burden J. Med. Econ. 2013 16 329 341 10.3111/13696998.2012.756397 23216014
Sethi S. Wadhwa V. LeClair J. Mikami S. Park R. Jones M. Sethi N. Brown A. Lembo A. In-patient discharge rates for the irritable bowel syndrome—An analysis of national trends in the United States from 1997 to 2010 Aliment. Pharmacol. Ther. 2013 38 1338 1346 10.1111/apt.12532 24206371
Lacy B.E. Pimentel M. Brenner D.M. Chey W.D. Keefer L.A. Long M.D. Moshiree B. ACG Clinical Guideline: Management of Irritable Bowel Syndrome Am. J. Gastroenterol. 2021 116 17 44 33315591 10.14309/ajg.0000000000001036
Vasant D.H. Paine P.A. Black C.J. Houghton L.A. Everitt H.A. Corsetti M. Agrawal A. Aziz I. Farmer A.D. Eugenicos M.P. et al. British Society of Gastroenterology guidelines on the management of irritable bowel syndrome Gut 2021 70 1214 1240 33903147 10.1136/gutjnl-2021-324598
Moayyedi P. Andrews C.N. MacQueen G. Korownyk C. Marsiglio M. Graff L. Kvern B. Lazarescu A. Liu L. Paterson W.G. et al. Canadian Association of Gastroenterology Clinical Practice Guideline for the Management of Irritable Bowel Syndrome (IBS) J. Can. Assoc. Gastroenterol. 2019 2 6 29 31294724 10.1093/jcag/gwy071
Fukudo S. Okumura T. Inamori M. Okuyama Y. Kanazawa M. Kamiya T. Sato K. Shiotani A. Naito Y. Fujikawa Y. et al. Evidence-based clinical practice guidelines for irritable bowel syndrome 2020 J. Gastroenterol. 2021 56 193 217 33538894 10.1007/s00535-020-01746-z
Lembo A. Sultan S. Chang L. Heidelbaugh J.J. Smalley W. Verne G.N. AGA Clinical practice guideline on the pharmacological management of irritable bowel syndrome with diarrhea Gastroenterology 2022 163 137 151 35738725 10.1053/j.gastro.2022.04.017
Chang L. Sultan S. Lembo A. Verne G.N. Smalley W. Heidelbaugh J.J. AGA Clinical Practice Guideline on the Pharmacological Management of Irritable Bowel Syndrome With Constipation Gastroenterology 2022 163 118 136 35738724 10.1053/j.gastro.2022.04.016
Savarino E. Zingone F. Barberio B. Marasco G. Akyuz F. Akpinar H. Barboi O. Bodini G. Bor S. Chiarioni G. et al. Functional bowel disorders with diarrhoea: Clinical guidelines of the United European Gastroenterology and European Society for Neurogastroenterology and Motility United Eur. Gastroenterol. J. 2022 10 556 584 35695704 10.1002/ueg2.12259
Jakobsson Ung E. Ringstrom G. Sjövall H. Simrén M. How patients with long-term experience of living with irritable bowel syndrome manage illness in daily life: A qualitative study Eur. J. Gastroenterol. Hepatol. 2013 25 1478 1483 10.1097/MEG.0b013e328365abd3 24047860
Bertram S. Kurland M. Lydick E. Locke G.R. 3rd Yawn B.P. The patient’s perspective of irritable bowel syndrome J. Fam. Pr. 2001 50 521 525 11401739
Di Rosa C. Altomare A. Terrigno V. Carbone F. Tack J. Cicala M. Guarino P.L. Constipation-Predominant Irritable Bowel Syndrome (IBS-C): Effects of Different Nutritional Patterns on Intestinal Dysbiosis and Symptoms Nutrients 2023 15 1647 10.3390/nu15071647 37049488
EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) EFSA Panel on Dietetic Products NaAN. Scientific opinion on the safety of ‘Chitin-glucan’ as a novel food ingredient EFSA J. 2010 8 1687 11401739 10.2903/j.efsa.2010.1687
Berecochea-Lopez A. Decordé K. Ventura E. Godard M. Bornet A. Teissèdre P.L. Cristol J.P. Rouanet J.M. Fungal chitin-glucan from Aspergillus niger efficiently reduces aortic fatty streak accumulation in the high-fat fed hamster, an animal model of nutritionally induced atherosclerosis J. Agric. Food Chem. 2009 57 1093 1098 19154104 10.1021/jf803063v
Neyrinck A.M. Possemiers S. Verstraete W. De Backer F. Cani P.D. Delzenne N.M. Dietary modulation of clostridial cluster XIVa gut bacteria (Roseburia spp.) by chitin-glucan fiber improves host metabolic alterations induced by high-fat diet in mice J. Nutr. Biochem. 2012 23 51 59 21411304 10.1016/j.jnutbio.2010.10.008
Calatayud M. Verstrepen L. Ghyselinck J. Van den Abbeele P. Marzorati M. Modica S. Ranjanoro T. Maquet V. Chitin Glucan Shifts Luminal and Mucosal Microbial Communities, Improve Epithelial Barrier and Modulates Cytokine Production In Vitro Nutrients 2021 13 3249 34579126 10.3390/nu13093249
Rodriguez J. Neyrinck A.M. Zhang Z. Seethaler B. Nazare J.A. Robles Sánchez C. Roumain M. Muccioli G.G. Bindels L.B. Cani P.D. et al. Metabolite profiling reveals the interaction of chitin-glucan with the gut microbiota Gut Microbes 2020 12 1810530 32893709 10.1080/19490976.2020.1810530
Valibouze C. Dubuquoy C. Chavatte P. Genin M. Maquet V. Modica S. Desreumaux P. Rousseaux C. Chitin-glucan improves important pathophysiological features of irritable bowel syndrome World J. Gastroenterol. 2024 30 2258 2271 10.3748/wjg.v30.i16.2258
McFarland L.V. Karakan T. Karatas A. Strain-specific and outcome-specific efficacy of probiotics for the treatment of irritable bowel syndrome: A systematic review and meta-analysis eClinicalMedicine 2021 41 101154 10.1016/j.eclinm.2021.101154
Goodoory V.C. Khasawneh M. Black C.J. Quigley E.M.M. Moayyedi P. Ford A.C. Efficacy of Probiotics in Irritable Bowel Syndrome: Systematic Review and Meta-analysis Gastroenterology 2023 165 1206 1218 10.1053/j.gastro.2023.07.018 37541528
Sanders M.E. Klaenhammer T. Invited Review: The scientific basis of Lactobacillus acidophilus NCFM functionality as a probiotic J. Dairy. Sci. 2001 84 319 331 10.3168/jds.S0022-0302(01)74481-5 11233016
Rousseaux C. Thuru X. Gelot A. Barnich N. Neut C. Dubuquoy L. Merour E. Geboes K. Chamaillard M. Ouwehand A. et al. Lactobacillus acidophilus modulates intestinal pain and induces opioid and cannabinoid receptors Nat. Med. 2007 13 35 37 10.1038/nm1521 17159985
Ringel-Kulka T. Goldsmith J.R. Carroll I.M. Barros S.P. Palsson O. Jobin C. Ringel Y. Lactobacillus acidophilus NCFM affects colonic mucosal opioid receptor expression in patients with functional abdominal pain—A randomised clinical study Aliment. Pharmacol. Ther. 2014 40 200 207 10.1111/apt.12800 24853043
D’Souza B. Slack T. Wong S.W. Lam F. Muhlmann M. Koestenbauer J. Dark J. Newstead G. Randomized controlled trial of probiotics after colonoscopy ANZ J. Surg. 2017 87 E65 E69 10.1111/ans.13225 26183594
Foligne B. Nutten S. Grangette C. Dennin V. Goudercourt D. Poiret S. Dewulf J. Brassart D. Mercenier A. Pot B. Correlation between in vitro and in vivo immune modulatory properties of lactic acid bacteria World J. Gastroenterol. 2007 13 236 243 17226902 10.3748/wjg.v13.i2.236
Engelbrektson A.L. Korzenik J.R. Sanders M.E. Clement B.G. Leyer G. Klaenhammer T.R. Kitts C.L. Analysis of treatment effects on the microbial ecology of the human intestine FEMS Microbiol. Ecol. 2006 57 239 250 16867142 10.1111/j.1574-6941.2006.00112.x
Stenman L.K. Patterson E. Meunier J. Roman F.J. Lehtinen M.J. Strain specific stress-modulating effects of candidate probiotics: A systematic screening in a mouse model of chronic restraint stress Behav. Brain Res. 2020 379 112376 31765723 10.1016/j.bbr.2019.112376
Patterson E. Griffin S.M. Ibarra A. Ellsiepen E. Hellhammer J. Lacticaseibacillus paracasei Lpc-37® improves psychological and physiological markers of stress and anxiety in healthy adults: A randomized, double-blind, placebo-controlled and parallel clinical trial (the Sisu study) Neurobiol. Stress. 2020 13 100277 33385020 PMC7770962 10.1016/j.ynstr.2020.100277
Johnson A.C. Farmer A.D. Ness T.J. Greenwood-Van Meerveld B. Critical evaluation of animal models of visceral pain for therapeutics development: A focus on irritable bowel syndrome Neurogastroenterol. Motil. 2020 32 e13776 31833625 10.1111/nmo.13776
Zimmermann M. Ethical guidelines for investigations of experimental pain in conscious animals Pain 1983 16 109 110 10.1016/0304-3959(83)90201-4 6877845
Bourdu S. Dapoigny M. Chapuy E. Artigue F. Vasson M.P. Dechelotte P. Bommelaer G. Eschalier A. Ardid D. Rectal instillation of butyrate provides a novel clinically relevant model of noninflammatory colonic hypersensitivity in rats Gastroenterology 2005 128 1996 2008 10.1053/j.gastro.2005.03.082 15940632
Rousseaux C. Lefebvre B. Dubuquoy L. Lefebvre P. Romano O. Auwerx J. Metzger D. Wahli W. Desvergne B. Naccari G.C. et al. Intestinal antiinflammatory effect of 5-aminosalicylic acid is dependent on peroxisome proliferator-activated receptor-gamma J. Exp. Med. 2005 201 1205 1215 10.1084/jem.20041948 15824083
Esquerre N. Basso L. Dubuquoy C. Djouina M. Chappard D. Blanpied C. Desreumaux P. Vergnolle N. Vignal C. Body-Malapel M. Aluminum Ingestion Promotes Colorectal Hypersensitivity in Rodents Cell Mol. Gastroenterol. Hepatol. 2019 7 185 196 30534582 10.1016/j.jcmgh.2018.09.012
van der Geest A.M. Schukking I. Brummer R.J.M. van de Burgwal L.H.M. Larsen O.F.A. Comparing probiotic and drug interventions in irritable bowel syndrome: A meta-analysis of randomised controlled trials Benef. Microbes 2022 13 183 194 10.3920/BM2021.0123
Principi N. Cozzali R. Farinelli E. Brusaferro A. Esposito S. Gut dysbiosis and irritable bowel syndrome: The potential role of probiotics J. Infect. 2018 76 111 120 10.1016/j.jinf.2017.12.013
Umeano L. Iftikhar S. Alhaddad S.F. Paulsingh C.N. Riaz M.F. Garg G. Mohammed L. Effectiveness of Probiotic Use in Alleviating Symptoms of Irritable Bowel Syndrome: A Systematic Review Cureus 2024 16 e58306 38752062 10.7759/cureus.58306
Ford A.C. Talley N.J. Mucosal inflammation as a potential etiological factor in irritable bowel syndrome: A systematic review Gastroenterol. 2011 46 421 431 21331765 10.1007/s00535-011-0379-9
Bashashati M. Moossavi S. Cremon C. Barbaro M.R. Moraveji S. Talmon G. Rezaei N. Hughes P.A. Bian Z.X. Choi C.H. et al. Colonic immune cells in irritable bowel syndrome: A systematic review and meta-analysis Neurogastroenterol. Motil. 2017 30 e13192 28851005 10.1111/nmo.13192
Simrén M. Tack J. New treatments and therapeutic targets for IBS and other functional bowel disorders Nat. Rev. Gastroenterol. Hepatol. 2018 15 589 605 29930260 10.1038/s41575-018-0034-5
Simon E. Călinoiu L.F. Mitrea L. Vodnar D.C. Probiotics, Prebiotics, and Synbiotics: Implications and Beneficial Effects against Irritable Bowel Syndrome Nutrients 2021 13 2112 10.3390/nu13062112 34203002
Mohamadzadeh M. Pfeiler E.A. Brown J.B. Zadeh M. Gramarossa M. Managlia E. Bere P. Sarraj B. Khan M.W. Pakanati K.C. et al. Regulation of induced colonic inflammation by Lactobacillus acidophilus deficient in lipoteichoic acid Proc. Natl. Acad. Sci. USA 2011 108 (Suppl. S1) 4623 4630 10.1073/pnas.1005066107 21282652
Dubuquoy L. Dharancy S. Nutten S. Pettersson S. Auwerx J. Desreumaux P. Role of peroxisome proliferator-activated receptor gamma and retinoid X receptor heterodimer in hepatogastroenterological diseases Lancet 2002 360 1410 1418 10.1016/S0140-6736(02)11395-X 12424006
Fumery M. Speca S. Langlois A. Davila A.M. Dubuquoy C. Grauso M. Martin Mena A. Figeac M. Metzger D. Rousseaux C. et al. Peroxisome proliferator-activated receptor gamma (PPARgamma) regulates lactase expression and activity in the gut EMBO Mol. Med. 2017 9 1471 1481 28947679 10.15252/emmm.201707795
Kapoor S. PPARalpha agonists—An emerging concept in the management of neuropathic and visceral pain Psychopharmacology 2012 221 537 538 22461105 10.1007/s00213-012-2694-0
Lucarini E. Micheli L. Pagnotta E. Toti A. Ferrara V. Ciampi C. Margiotta F. Martelli A. Testai L. Calderone V. et al. The Efficacy of Camelina sativa Defatted Seed Meal against Colitis-Induced Persistent Visceral Hypersensitivity: The Relevance of PPAR alpha Receptor Activation in Pain Relief Nutrients 2022 14 3137 35956313 10.3390/nu14153137
Ranaivo H. Zhang Z. Alligier M. Van Den Berghe L. Sothier M. Lambert-Porcheron S. Feugier N. Cuerq C. Machon C. Neyrinck A.M. et al. Chitin-glucan supplementation improved postprandial metabolism and altered gut microbiota in subjects at cardiometabolic risk in a randomized trial Sci. Rep. 2022 12 8830 10.1038/s41598-022-12920-z
Adolph T.E. Meyer M. Jukic A. Tilg H. Heavy arch: From inflammatory bowel diseases to metabolic disorders Gut 2024 73 1376 1387 10.1136/gutjnl-2024-331914
Ghusn W. Loftus E.V. Jr. Johnson A.M. Reviewing the impact of obesity on inflammatory bowel disease and considerations for optimizing management Curr. Opin. Gastroenterol. 2024 40 268 275 10.1097/MOG.0000000000001025
Je Y. Han K. Chun J. Kim Y. Kim J.H. Youn Y.H. Park H. Im J.P. Kim J.S. Association of Waist Circumference with the Risk of Inflammatory Bowel Disease: A Nationwide Cohort Study of Million Individuals in Korea J. Crohn’s Colitis 2023 17 681 692 10.1093/ecco-jcc/jjac193
Drouet M. Dubuquoy L. Desreumaux P. Bertin B. Visceral fat and gut inflammation Nutrition 2012 28 113 117 10.1016/j.nut.2011.09.009 22208553
